Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MODICON 21 vs LARIN 1.5/30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH) from pituitary via negative feedback, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; induces endometrial thinning.
Combination oral contraceptive: ethinyl estradiol suppresses FSH and LH, preventing ovulation; norethindrone induces endometrial changes and increases cervical mucus viscosity, impeding sperm penetration.
Prevention of pregnancy
Prevention of pregnancy
One tablet (norethindrone 0.5 mg and ethinyl estradiol 0.035 mg) orally once daily for 21 consecutive days, followed by 7 drug-free days.
One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets.
Terminal elimination half-life: 12–18 hours; clinical context: steady-state reached after 3–5 days of daily dosing
Ethinyl estradiol: 13-19 hours; Norethindrone: 7-9 hours. Steady-state achieved in ~5-7 days.
Ethinyl estradiol undergoes hepatic CYP3A4-mediated hydroxylation and conjugation; norethindrone is reduced and conjugated in liver.
Ethinyl estradiol: primarily CYP3A4; norethindrone: primarily CYP3A4, with some reduction to active metabolites.
Renal (80% as metabolites, 20% unchanged); biliary/fecal (minor, <5% total)
Renal (40% as metabolites, <10% unchanged); fecal (50% as metabolites); biliary (minor).
Ethinylestradiol: 97% bound to albumin; Norethindrone: 80% bound to albumin and SHBG
Ethinyl estradiol: 97-98% bound to albumin; Norethindrone: 93-99% bound to SHBG and albumin.
Ethinylestradiol: 2–4 L/kg; Norethindrone: 3–5 L/kg; large Vd indicates extensive tissue distribution
Ethinyl estradiol: 2.5-5 L/kg; Norethindrone: 2-4 L/kg. Indicates extensive tissue distribution.
Oral: 40–60% (first-pass metabolism reduces systemic availability)
Oral: Ethinyl estradiol ~40-50% (first-pass metabolism); Norethindrone ~50-60% (first-pass metabolism).
No dose adjustment required for chronic kidney disease. Contraindicated in acute renal failure or severe renal impairment (GFR <30 m L/min) due to potential fluid retention and electrolyte disturbances.
No dose adjustment required in mild to moderate renal impairment (Cr Cl >=30 m L/min). Use contraindicated in severe renal impairment (Cr Cl <30 m L/min) or renal failure due to potential for fluid retention and hyperkalemia.
Contraindicated in acute hepatic disease, hepatic adenomas, or impaired liver function (Child-Pugh class B or C). For mild hepatic impairment (Child-Pugh class A), use with caution; monitor liver function.
Contraindicated in Child-Pugh class B or C (moderate to severe hepatic impairment). For Child-Pugh class A, lowest possible effective dose should be used with close monitoring of liver function.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal minors established; dose same as adults (one tablet daily for 21 days, then 7 days off).
Post-menarche adolescents: same dosing as adults (one tablet daily for 21 days, then 7 days placebo). Safety and efficacy in pre-menarche girls have not been established.
Not indicated for use in postmenopausal women. No specific dose adjustments for elderly due to lack of indication; consider increased risk of cardiovascular and thrombotic events in women over 35 who smoke.
Not indicated for postmenopausal women. No specific geriatric dose adjustments; however, consider increased risk of thromboembolic events and cardiovascular disease in women aged >40 years who smoke or have other risk factors.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day); women >35 years who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Thrombotic disorders (thrombophlebitis, venous thromboembolism, arterial thromboembolism),Cardiovascular disease (e.g., myocardial infarction, stroke) especially in smokers >35,Liver disease (e.g., hepatic adenoma, hepatocellular carcinoma),Elevated blood pressure,Gallbladder disease,Carbohydrate/lipid metabolic effects,Ocular lesions (e.g., retinal thrombosis),Headache/migraine,Bleeding irregularities,Depression
Cardiovascular disease risk: smoking, hypertension, diabetes, hyperlipidemia,Thromboembolic events: increased risk in surgery, postpartum, or immobilization,Liver disease: discontinue if jaundice develops,Gallbladder disease: increased risk,Glucose intolerance: monitor in diabetics,Blood pressure elevation: monitor periodically,Depression: discontinue if severe
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking and age >35 years
Current or history of venous thromboembolism,Cerebrovascular or coronary artery disease,Uncontrolled hypertension,Diabetes with vascular involvement,Known or suspected pregnancy,Liver tumors or active liver disease,Undiagnosed abnormal uterine bleeding,Hypersensitivity to any component,Cigarette smoking in women over 35
No specific food restrictions; however, grapefruit juice may increase estrogen levels slightly (theoretical). Maintain consistent intake of folate-rich foods as oral contraceptives may lower folate levels. Avoid St. John's wort (herbal) as it reduces contraceptive efficacy.
Grapefruit juice may increase ethinyl estradiol levels; avoid excessive consumption. No specific dietary restrictions; can be taken with or without food.
Modicon 21 is a combination oral contraceptive. First trimester: Epidemiologic studies have not shown an increased risk of birth defects with inadvertent exposure. Second and third trimesters: Use is not indicated during pregnancy; fetal and neonatal risks include cardiovascular and genitourinary anomalies, though data are limited and confounded by maternal condition.
First trimester: No consistent evidence of major malformations, but a small increased risk of cardiovascular defects and oral clefts cannot be excluded. Second and third trimesters: Associated with adverse fetal outcomes including low birth weight, preterm delivery, and neonatal withdrawal symptoms. Avoid use during pregnancy due to known risks.
Combination hormonal contraceptives reduce milk production and may pass into breast milk. M/P ratio not established. Use in breastfeeding is generally not recommended until breastfeeding is well-established (typically after 6 weeks postpartum).
Small amounts of ethinyl estradiol and norethindrone transfer into breast milk, with a milk-to-plasma ratio approximately 0.2-0.3 for norethindrone and <0.1 for ethinyl estradiol. May reduce milk production and composition. Use caution and consider alternative contraception in nursing mothers.
Not applicable as Modicon 21 is contraindicated during pregnancy. No dose adjustment is needed.
Contraindicated in pregnancy; no dose adjustment is applicable as the drug should be discontinued immediately upon confirmed pregnancy.
MODICON 21 (norethindrone/ethinyl estradiol) is a monophasic oral contraceptive. Administer starting on day 1 of menstrual period (Sunday start or day 1 start). Breakthrough bleeding is common in first cycles; sustained bleeding warrants evaluation. Missed dose protocol: if one pill is missed, take it ASAP and continue schedule; if two or more missed, use backup contraception for 7 days. Advise against smoking due to increased thrombotic risk, especially in women over 35. Assess for contraindications: history of DVT/PE, migraine with aura, breast cancer, liver disease, uncontrolled hypertension, etc. Drug interactions: rifampin, anticonvulsants (phenytoin, carbamazepine), St. John's wort may reduce efficacy.
Larin 1.5/30 is a monophasic combination oral contraceptive containing 1.5 mg norethindrone acetate and 30 mcg ethinyl estradiol. It is indicated for prevention of pregnancy and may also be used for management of acne and menstrual disorders. Advise patients to take at the same time daily to maintain consistent hormone levels. Counsel about breakthrough bleeding, especially during first cycles. Monitor for thrombotic events; use with caution in women with migraine with aura, hypertension, or smoking history over age 35. Effectiveness may be reduced with strong CYP3A4 inducers. Consider alternative contraception if patient is on chronic enzyme-inducing drugs. Use of NSAIDs can increase risk of breakthrough bleeding. Not recommended during breastfeeding or pregnancy.
Take one pill daily at the same time each day for 21 days, then 7 days off.,If you miss a pill, follow the missed dose instructions in the package insert.,Use backup contraception (e.g., condoms) if you miss two or more pills.,Do not smoke while taking this medication; smoking increases risk of blood clots.,Report any sudden severe headache, chest pain, leg swelling, or vision changes immediately.,You may experience irregular bleeding, nausea, or breast tenderness initially.,This medication does not protect against sexually transmitted infections.,Check with your doctor before starting any new medications, including herbal supplements.
Take one tablet at the same time each day, with or without food.,If you miss a dose, follow the instructions in the package insert; use backup contraception if needed.,Common side effects include nausea, breast tenderness, headache, and breakthrough bleeding, especially in the first few months.,Seek medical attention if you experience leg pain, chest pain, shortness of breath, severe headache, vision changes, or jaundice.,Do not smoke while taking this medication as it increases the risk of serious cardiovascular side effects.,Inform your healthcare provider of all medications you are taking, including over-the-counter drugs and supplements.,This medication does not protect against sexually transmitted infections; use condoms for STI prevention.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MODICON 21 vs LARIN 1.5/30, answered by our medical review team.
MODICON 21 is a Combination Oral Contraceptive that works by Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH) from pituitary via negative feedback, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; induces endometrial thinning.. LARIN 1.5/30 is a Combination Oral Contraceptive that works by Combination oral contraceptive: ethinyl estradiol suppresses FSH and LH, preventing ovulation; norethindrone induces endometrial changes and increases cervical mucus viscosity, impeding sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MODICON 21 and LARIN 1.5/30 depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MODICON 21 is: One tablet (norethindrone 0.5 mg and ethinyl estradiol 0.035 mg) orally once daily for 21 consecutive days, followed by 7 drug-free days.. The standard adult dose of LARIN 1.5/30 is: One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MODICON 21 and LARIN 1.5/30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MODICON 21 is classified as Category C. Modicon 21 is a combination oral contraceptive. First trimester: Epidemiologic studies have not shown an increased risk of birth defects with inadvertent exposure. Second and third. LARIN 1.5/30 is classified as Category C. First trimester: No consistent evidence of major malformations, but a small increased risk of cardiovascular defects and oral clefts cannot be excluded. Second and third trimesters. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.